Enveda secures $311M to advance AI-discovered natural drugs
Biotech startup Enveda has closed a $311 million Series E funding round, doubling its valuation to $2 billion. The company utilizes artificial intelligence to discover novel therapeutic compounds derived from natural sources such as plants and microbes, moving beyond traditional laboratory synthesis. Founded in 2019 by Viswa Colluru, Enveda stands out by successfully advancing AI-discovered […]
Continue Reading